Security key
M40527109
Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX)
CUSIP: M40527109
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Ordinary shares, par value NIS 0.0000769 per share
- Shares outstanding
- 45,504,462
- Total 13F shares
- 2,569,162
- Share change
- -261,684
- Total reported value
- $2,166,115
- Put/Call ratio
- 0%
- Price per share
- $0.84
- Number of holders
- 10
- Value change
- -$314,934
- Number of buys
- 6
- Number of sells
- 3
Report period
Q2 2023
Institutions
10
Top holders
10
ENTX full security history
Newer quarter: Q3 2023
Previous quarter: Q1 2023
Entera Bio Ltd. SEC filings
Entera Bio Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M40527109
Recent filing periods:
Top shareholders of ENTX - Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC |
13F
|
Company |
5.5%
|
2,484,275
|
$2,881,759 | — | 31 Mar 2023 | |
| Phillip Schwartz |
3/4/5
|
President of R&D, Director |
—
class O/S missing
|
607,410
|
$601,336 | — | 20 Jan 2022 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
0.65%
|
295,966
|
$343,321 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
17,597
|
$20,412 | — | 31 Mar 2023 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.02%
|
10,400
|
$12,000 | — | 31 Mar 2023 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.02%
|
10,000
|
$11,600 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0.02%
|
9,740
|
$11,298 | — | 31 Mar 2023 | |
| Ramesh Ratan |
3/4/5
|
U.S.based CFO |
—
class O/S missing
|
10,000
|
$9,900 | — | 19 Jan 2022 | |
| Spiros Jamas |
3/4/5
|
Chief Executive Officer |
—
class O/S missing
|
10,000
|
$9,900 | — | 18 Jan 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
1,868
|
$2,000 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
1,000
|
$1,160 | — | 31 Mar 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
576
|
$1,000 | — | 31 Mar 2023 | |
| Arthur C. Santora II |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
35,000
|
— | — | 24 Apr 2023 |
Institutional Holders of Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX) as of Q2 2023
As of 30 Jun 2023,
Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,569,162 shares.
The largest 10 holders included
Knoll Capital Management, LLC, HRT FINANCIAL LP, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, HighTower Advisors, LLC, PNC Financial Services Group, Inc., MORGAN STANLEY, UBS Group AG, OSAIC HOLDINGS, INC., and CITADEL ADVISORS LLC.
This page lists
10
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
8
Q2 2023 holders
10
Holder diff
2
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.